ARMATA PHARMACEUTICALS INC
NYSE: ARMP (Armata Pharmaceuticals, Inc.)
Last update: yesterday, 10:34PM7.58
0.11 (1.47%)
| Previous Close | 7.47 |
| Open | 7.33 |
| Volume | 75,836 |
| Avg. Volume (3M) | 62,731 |
| Market Cap | 278,267,936 |
| Price / Book | 2.11 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2026 |
| Profit Margin | -9.07% |
| Operating Margin (TTM) | -1,668.23% |
| Diluted EPS (TTM) | -0.400 |
| Quarterly Revenue Growth (YOY) | -49.20% |
| Current Ratio (MRQ) | 0.120 |
| Operating Cash Flow (TTM) | -34.55 M |
| Levered Free Cash Flow (TTM) | -30.48 M |
| Return on Assets (TTM) | -24.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Armata Pharmaceuticals, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 69.55% |
| % Held by Institutions | 2.13% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Asset Management, Llc | 31 Mar 2026 | 2,107,675 |
| Dauntless Investment Group, Llc | 31 Mar 2026 | 90,580 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |